Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) EBIT Margin (2020 - 2025)

Historic EBIT Margin for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to 40.14%.

  • RxSight's EBIT Margin fell 140100.0% to 40.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 32.01%, marking a year-over-year decrease of 15500.0%. This contributed to the annual value of 26.34% for FY2024, which is 298900.0% up from last year.
  • As of Q3 2025, RxSight's EBIT Margin stood at 40.14%, which was down 140100.0% from 41.63% recorded in Q2 2025.
  • RxSight's 5-year EBIT Margin high stood at 21.46% for Q4 2024, and its period low was 319.6% during Q1 2021.
  • In the last 5 years, RxSight's EBIT Margin had a median value of 65.47% in 2023 and averaged 105.26%.
  • Per our database at Business Quant, RxSight's EBIT Margin crashed by -2621600bps in 2021 and then skyrocketed by 1443600bps in 2022.
  • RxSight's EBIT Margin (Quarter) stood at 174.02% in 2021, then skyrocketed by 46bps to 93.18% in 2022, then skyrocketed by 59bps to 37.97% in 2023, then soared by 43bps to 21.46% in 2024, then crashed by -87bps to 40.14% in 2025.
  • Its EBIT Margin was 40.14% in Q3 2025, compared to 41.63% in Q2 2025 and 28.17% in Q1 2025.